Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $4.25.
Several brokerages have recently issued reports on MRSN. Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Mersana Therapeutics in a research note on Monday, March 3rd. William Blair began coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They issued an “outperform” rating on the stock.
Read Our Latest Research Report on Mersana Therapeutics
Institutional Trading of Mersana Therapeutics
Mersana Therapeutics Trading Up 3.0 %
MRSN opened at $0.48 on Thursday. Mersana Therapeutics has a 52 week low of $0.44 and a 52 week high of $5.11. The business has a fifty day simple moving average of $0.62 and a 200-day simple moving average of $1.49. The firm has a market cap of $59.70 million, a P/E ratio of -0.79 and a beta of 1.67. The company has a quick ratio of 2.35, a current ratio of 2.35 and a debt-to-equity ratio of 13.35.
Mersana Therapeutics (NASDAQ:MRSN – Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The business had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. On average, equities analysts expect that Mersana Therapeutics will post -0.62 earnings per share for the current year.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.
See Also
- Five stocks we like better than Mersana Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Can TikTok Stock Picks Really Make You Rich?
- How to Read Stock Charts for Beginners
- The “Quality” Rotation: Back to Basics Investing
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.